Hepatitis Monthly

Published by: Kowsar

Characterization of HCV Genotype 5a Envelope Proteins: Implications for Vaccine Development and Therapeutic Entry Target

Maemu Petronella Gededzha 1 , * , Maphahlanganye Jeffrey Mphahlele 1 and Selokela Gloria Selabe 1
Authors Information
1 Department of Virology, HIV and Hepatitis Research Unit, University of Limpopo, Medunsa Campus/National Health Laboratory Service, Pretoria, South Africa
Article information
  • Hepatitis Monthly: November 30, 2014, 14 (11); e23660
  • Published Online: November 22, 2014
  • Article Type: Research Article
  • Received: September 15, 2014
  • Revised: October 8, 2014
  • Accepted: October 26, 2014
  • DOI: 10.5812/hepatmon.23660

To Cite: Gededzha M P, Mphahlele M J, Selabe S G. Characterization of HCV Genotype 5a Envelope Proteins: Implications for Vaccine Development and Therapeutic Entry Target, Hepat Mon. 2014 ; 14(11):e23660. doi: 10.5812/hepatmon.23660.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Guidelines for the screening care and treatment of persons with hepatitis C infection. 2014;
  • 2. Lemon SM, Walker C, Alter MJ, Yi M. Fields Virology. 2007; : 1253-304
  • 3. Chevaliez S, Pawlotsky JM. Hepatitis C Viruses: Genomes and Molecular Biology. 2006; : 45-7
  • 4. Drummer HE, Maerz A, Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett. 2003; 546(2-3): 385-90[PubMed]
  • 5. Goffard A, Dubuisson J. Glycosylation of hepatitis C virus envelope proteins. Biochimie. 2003; 85(3-4): 295-301[PubMed]
  • 6. Higginbottom A, Quinn ER, Kuo CC, Flint M, Wilson LH, Bianchi E, et al. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol. 2000; 74(8): 3642-9[PubMed]
  • 7. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002; 21(19): 5017-25[PubMed]
  • 8. Ashfaq UA, Qasim M, Yousaf MZ, Awan MT, Jahan S. Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies. J Transl Med. 2011; 9: 194[DOI][PubMed]
  • 9. Brown RJ, Tarr AW, McClure CP, Juttla VS, Tagiuri N, Irving WL, et al. Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. J Gen Virol. 2007; 88: 458-69[DOI][PubMed]
  • 10. Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM, Chambers TJ. HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology. 2004; 319(1): 36-48[DOI][PubMed]
  • 11. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science. 1998; 282(5390): 938-41[PubMed]
  • 12. Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci. 2008; 65(1): 100-12[DOI][PubMed]
  • 13. Schonning K, Jansson B, Olofsson S, Hansen JE. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J Gen Virol. 1996; 77 ( Pt 4): 753-8[PubMed]
  • 14. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929): 307-12[DOI][PubMed]
  • 15. Bugli F, Mancini N, Kang CY, Di Campli C, Grieco A, Manzin A, et al. Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol. 2001; 75(20): 9986-90[DOI][PubMed]
  • 16. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A. 2012; 109(16): 6205-10[DOI][PubMed]
  • 17. Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, et al. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol. 2001; 75(24): 12088-97[DOI][PubMed]
  • 18. El-Awady MK, Tabll AA, Atef K, Yousef SS, Omran MH, El-Abd Y, et al. Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. World J Gastroenterol. 2006; 12(16): 2530-5[PubMed]
  • 19. El-Awady MK, Tabll AA, El-Abd YS, Yousif H, Hegab M, Reda M, et al. Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. Virol J. 2009; 6: 66[DOI][PubMed]
  • 20. Baldick CJ, Wichroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 2010; 6(9)[DOI][PubMed]
  • 21. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011; 474(7350): 208-11[DOI][PubMed]
  • 22. Sainz BJ, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012; 18(2): 281-5[DOI][PubMed]
  • 23. Mittapalli GK, Zhao F, Jackson A, Gao H, Lee H, Chow S, et al. Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor. Bioorg Med Chem Lett. 2012; 22(15): 4955-61[DOI][PubMed]
  • 24. Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, et al. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis. 2012; 205(4): 656-62[DOI][PubMed]
  • 25. Gededzha MP, Selabe SG, Kyaw T, Rakgole JN, Blackard JT, Mphahlele MJ. Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa. J Med Virol. 2012; 84(4): 601-7[DOI][PubMed]
  • 26. Gededzha MP, Selabe SG, Blackard JT, Kyaw T, Mphahlele MJ. Near full-length genome analysis of HCV genotype 5 strains from South Africa. Infect Genet Evol. 2014; 21: 118-23[DOI][PubMed]
  • 27. Koletzki D, Dumont S, Vermeiren H, Peixe P, Nina J, Camacho RJ, et al. Full genome sequence of three isolates of hepatitis C virus subtype 4b from Portugal. Arch Virol. 2009; 154(1): 127-32
  • 28. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD. The Proteomics Protocols Handbook. 2005; : 571-607
  • 29. Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006; 65(1): 40-8[DOI][PubMed]
  • 30. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol. 1999; 294(5): 1351-62[DOI][PubMed]
  • 31. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatol. 2004; 39(1): 5-19
  • 32. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, et al. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol. 2005; 43(4): 1902-9
  • 33. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, Mihalik K, et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A. 2009; 106(18): 7537-41[DOI][PubMed]
  • 34. Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, Irving WL, et al. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol. 2012; 86(5): 2739-49[DOI][PubMed]
  • 35. Manzin A, Solforosi L, Petrelli E, Macarri G, Tosone G, Piazza M, et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol. 1998; 72(7): 6271-6[PubMed]
  • 36. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A. 1994; 91(16): 7792-6[PubMed]
  • 37. Ikram A, Anjum S, Tahir M. In Silico Identification and Conservation Analysis of B-cell and T-Cell Epitopes of Hepatitis C Virus 3a Genotype Enveloped Glycoprotein 2 From Pakistan: A Step Towards Heterologous Vaccine Design. Hepat Mon. 2014; 14(6)[DOI][PubMed]
  • 38. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, Brunak S, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol. 2002; 76(17): 8757-68[PubMed]
  • 39. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004; 54(2): 333-40[DOI][PubMed]
  • 40. Hrobowski YM, Garry RF, Michael SF. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J. 2005; 2: 49[DOI][PubMed]
  • 41. Bai F, Town T, Pradhan D, Cox J, Ledizet M, et al. Antiviral peptides targeting the west nile virus envelope protein. J Virol. 2007; 81(4): 2047-55[DOI][PubMed]
  • 42. Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. Antiviral Res. 2010; 86(2): 172-9[DOI][PubMed]
  • 43. Wang G. Post-translational Modifications of Natural Antimicrobial Peptides and Strategies for Peptide Engineering. Curr Biotechnol. 2012; 1(1): 72-9[PubMed]
  • 44. Beyene A, Basu A, Meyer K, Ray R. Hepatitis C virus envelope glycoproteins and potential for vaccine development. Vox Sang. 2002; 83 Suppl 1: 27-32[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments